Homebusiness News

Lupin launches new drug used in the treatment of schizophrenia

Lupin launches new drug used in the treatment of schizophrenia

Lupin launches new drug used in the treatment of schizophrenia
Read Time
1 Min(s) Read
Profile image

By CNBCTV18.COMOct 20, 2022 5:45:10 PM IST (Published)

Shares down 1.40% to trade at Rs 678.50 on BSE.

wealth-desk wealth-desk

Buy / Sell Lupin share

Recommended Articles

View All

Lupin announced the launch of Paliperidone Extended-Release Tablets on Thursday, to market a generic equivalent of Invega Extended-Release Tablets of Janssen Research and Development.


Lupin will market the tablets in 1.5 mg, 3 mg, 6 mg and 9 mg forms.

Paliperidone Extended-Release is an antipsychotic drug used in the treatment of mental disorders.

Invega had estimated annual sales of $112 million in the US for Paliperidone Extended-Release Tablets, as per the IQVIA data of August 2022.

The company will also acquire all rights to two inhalation medicines - Brovana Inhalation Solution and Xopenex Inhalation Aerosol from Sunovion Pharmaceuticals Inc. for a cash consideration $75 million.

Shares of Lupin ended 1.9 percent lower on Thursday at Rs 676.20.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Most Read

Market Movers

View All
Top GainersTop Losers
CurrencyCommodities
CompanyPriceChng%Chng